Summary In a consecutive series of studies, 164 patients with symptomatic and/or visceral metastatic malignant melanoma were treated with single agent vindesine, high dose melphalan with autologous bone marrow transplantation (ABMT), high dose BCNU with ABMT or the BOLD (bleomycin, vincristine, CCNU and DTIC) combination. The high dose treatments and the combination chemotherapy resulted in significantly higher response rates but no prolongation of survival. Factors associated with longer survival included the absence of visceral metastases, the absence of bulky disease and good performance status. For all treatments, life 
Although the results of chemotherapy for malignant melanoma vary between institutions and according to the criteria used to evaluate response, it is well recognised that its efficacy is disappointing. In order to improve on these results, several possible avenues have been open for exploration. First the dosage of drugs can be escalated. Using this approach, we have used high dose melphalan (HDM) and high dose BCNU (HDBCNU) with autologous bone marrow transplantation. The second avenue is the use of chemotherapeutic agents in combination. Claims for improved responses in the treatment of malignant melanoma have been made with the use of drug combinations (Voight & Kleeberg, 1984; Abele et al., 1981; Cohen et al., 1986; Bajetta et al., 1985) particularly the BOLD and related regimens (bleomycin, vincristine, CCNU and DTIC) (Siegler et al., 1980; Young et al., 1985) . In our institution over the past decade we have sequentially studied the value of single agent chemotherapy in conventional dose (vindesine, VDN), high dose chemotherapy (HDM, HDBCNU) and most recently combination chemotherapy (BOLD), and we report and compare these studies here.
Methods and patients

Study method
One of us (S.L.) carried out a retrospective analysis of all patients treated between 1976 and 1986 with one of the four treatment schedules (VDN, HDM, HDBCNU, BOLD) . Throughout the study we have followed the principle that metastatic malignant melanoma should only be treated with chemotherapy if it is causing symptoms or threatening life. For this reason the patients were treated with chemotherapy only if they had symptomatic metastatic disease or they had progressive visceral metastases whether symptomatic or not. Patients with asymptomatic cutaneous or subcutaneous disease alone were not given chemotherapy. A consistent policy for indications for treatment and criteria of response has been used throughout the study. The study was a sequential one and the regimens were exchanged and new programmes started as the lack of efficacy became apparent. HDBCNU BCNU was given at a dose of 800 mg m2 dissolved in 12 ml of alcohol solvent (Mbidde et al., 1988 Cornbleet et al. (1983) and Mbidde et al. (1988) respectively. The toxicity pattern of these drugs is Figure 2 a, The cumulative probability of survival for patients treated with all regimens divided according to response or non-response to chemotherapy. All patients.
Responders; ..... Non-responders. b, The cumulative probability of survival for patients treated with all regimens divided according to response or non-response to chemotherapy. Excluding patients who died within 3 months of receiving their chemotherapy.
Responders; . Non-responders. Treatment with drugs other than VDN increased the chances of response (OR= 11.6; 95% CI 2.5, 53.2; P=0.001); patients aged under 45 had a higher chance of response (independent of treatment) (OR= 3.4; 95% CI 1.1, 10.5; P = 0.03); those whose primary tumour was on a limb had an increased chance of obtaining a response (OR = 3.1; 95% CI 1.1, 8.4; P = 0.03) to first mainline treatment.
All other variables appeared to be of no value in predicting for response when considered either univariately or multivariately.
Survival from first metastases The following variables were considered in a univariate analysis as possible prognostic factors for survival from first metastases: age (< 45 years, > 45 years), sex, performance status (WHO 0, 2, 2 +), primary site (head and neck, trunk, limbs, other), indication for treatment (asymptomatic progression, pain, bulk, other), site of first metastases (nodal, skin, visceral involvement) and treatment regimen (VDN, HDM, HDBCNU, BOLD). Site of first metastases was found to be a strong prognostic factor and this effect was completely described by whether or not the site of first metastases included visceral involvement, (log rank test = 24.05; d.f. = 1, P< 0.0005). Whether or not the site of the first metastases included lymph nodes or skin was not found to be of any significant prognostic importance. The importance of site of the primary tumour, considered on four levels (see above), did not reach conventional statistical significance (log rank test = 6.62; d.f. = 3, P = 0.09), but some variation between sites does appear to exist, and if we consider the dichotomous categorisation of limbs versus rest of body then we observed that patients whose primary tumour is situated on a limb have a better prognosis than the others (log rank test = 5.64; d.f. = 1; P = 0.018). Decreasing performance status resulted in a poorer prognosis (log rank test = 7.26; d.f. = 1, P = 0.007). Indication for treatment was found to be of significant prognostic value (log rank test = 11.40; d.f. = 3, P = 0.010), poorer prognosis being seen in those patients whose indications were bulk of disease or 'other' (see above). Age and sex were not found to be of significant prognostic value. Treatment regimen did not influence survival from first metastases (log rank test = 1.97; d.f. = 3, P = 0.58).
Cox proportional hazards regression analysis The variables described above in the univariate analysis were considered in the multivariate situation. Survival from first metastases A final model was obtained which included significant prognostic factors in decreasing order of importance for visceral involvement at first metastases (OR= 2.6; 95% CI 1.7, 3.9; P<0.001), performance status (WHO grade 2 or worse: OR = 1.7; 95% CI 1.1, 2.7; P = 0.017), indication for treatment (odds ratios are compared with the risk of death in patients treated for asymptomatic progression) (pain: OR = 0.96; 95% CI 0.65, 1.4; bulk of disease: OR= 2.8; 95% CI 1.4, 5.6; 'other': OR = 1.3; 95% CI 0.80, 2.1; heterogeneity test P = 0.029) and primary site (limb: OR = 0.71; 95% CI 0.51, 1.0; P = 0.046). Survival from start of treatment A final model was obtained which included significant prognostic factors for performance status (WHO grade 2 or worse: OR= 2.0; 95% CI 1.3, 3.1; P = 0.003) and indication for treatment (compared with asymptomatic progression) (pain: OR = 1.3; 95% CI 0.89, 1.9; bulk of disease: OR= 3.0; 95% CI 2.1, 6.1; 'other': OR = 1.7; 95% CI 1.0, 2.9; heterogeneity test P = 0.001). Site for first metastases was not found to be of any prognostic value.
If, in addition, response to treatment is considered as a potential prognostic factor for all patients, the model obtained included significant prognostic factors for response status (CR + PR: OR= 2.4; 95% CI 1.4, 3.9; P<0.001), performance status (WHO grade 2 or worse: OR = 2.0; 95% CI 1.3, 3.0; P = 0.004) and indication for treatment (compared with asymptomatic progression) (pain: OR = 1.4; 95% CI 0.98, 2.1; bulk of disease: OR= 3.4; 95% CI 1.7, 6.8; 'other': OR = 1.8; 95% CI 1.1, 3.1; P = 0.004 (Nelimark et al., 1983; Retsas et al., 1979; Quagliana et al., 1984) and for BOLD combination chemotherapy response rates up to 46% are recorded (Ahn et al., 1983; Reintgen et al., 1983) although our results are in keeping with the most recent report with this regimen of 24% (York & Foltz, 1988) .
There are two reasons why we expect our response rates for BOLD and VDN to be lower than those from other institutions. First we have reserved the use of chemotherapy for a palliative role in a relatively late stage of the disease. The median time from diagnosis of metastases to treatment was 5.5 months. Patients with asymptomatic skin and subcutaneous metastases are not given chemotherapy. Second, we have rigorously applied response criteria using the WHO system so that response is required at all measurable sites. The response rates may also be reduced because of the short duration of treatment in some patients on VDN and BOLD (eight patients in the BOLD group received only one course and 10 patients in VDN group received two or less courses). This is unlikely to be an important feature because most of those patients had progressed after their initial treatments making subsequent response unlikely. Nevertheless, our response rate to vindesine may have been reduced by our conservative use of the drug. If this is the case, then the failure of the more intensive regimens to prolong life is even more disappointing.
A small proportion of patients went on to receive second line chemotherapy after failure of their initial treatment. We have considered whether the use of the more intensive regimens as second line treatment might have reduced the evidence for any survival benefit in this comparison. The small number of patients who received second line treatment, and the very low response rate to this, suggests that this is not the case.
There appears to be no survival advantage in the numbers of patients studied here in the choice of the more intensive regimens despite their association with higher response rates. This is apparent on inspection of the survival curves and confirmed by univariate and multivariate analyses. This situation is not uncommon in clinical oncology (Selby & McElwain, 1986 ) especially when most responses are partial and when complete responses tend to occur at non-life threatening sites. The factors associated with response to chemotherapy are similar to those associated with a favourable natural history. The fit patient is likely to have a response of his tumour to drugs but he would also live longer if untreated. The association between response and survival seems not to be a causal relationship under these circumstances.
The purpose of chemotherapy is wider than only to prolong life. Response is usually associated with symptomatic relief and hence may improve the quality of life in some cases although toxicity and time in hospital have to be considered. Some symptomatic improvement was noted in patients who failed to even achieve a partial remission and the proportion doing so was higher in the intensive regimes.
The main goal of research into the treatment of metastatic malignant melanoma must remain the development of new cytotoxic or biological drugs rather than further work with conventional agents.
